USANA Health Sciences Inc. - 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for the period ended March 29, 1997. USANA Health Sciences Inc. develops, manufactures, and markets nutritional supplements, antioxidants, weight loss products, and natural skin and hair care products. The company operates through a network marketing system of independent distributors. As of April 28, 1997, there were 6,355,119 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 1997 | Q1 1996 |
|---|---|---|
| Net Sales | $17,654,299 | $10,554,160 |
| Gross Profit | $13,895,249 | $8,516,402 |
| Gross Margin | 78.7% | 80.7% |
| Net Earnings | $1,123,283 | $1,118,958 |
| Earnings Per Share (EPS) | $0.18 | $0.18 |
| Operating Cash Flow | $2,200,100 | $602,813 |
| Cash and Equivalents (End of Period) | $1,340,586 | $2,363,325 |
| Short-Term Borrowings | $0 | $1,500,000 |
| Working Capital | $1,819,431 | $457,277 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 67.3% year-over-year, driven by growth in the independent distributor base in the U.S. and Canada, successful regional conventions, and restored goodwill following a customer service software conversion.
- Margin Compression: Gross margin decreased from 80.7% to 78.7% due to a sales mix shift toward lower-margin products. Distributor incentives rose to 47.3% of net sales (from 45.6%) due to higher sales volume and fewer sales of non-commissionable sales aids.
- Expense Increases: Selling, general, and administrative (SG&A) expenses increased 85.2% to $3.4 million, attributed to facility expansion, senior management hiring, and software implementation inefficiencies. R&D spending more than doubled to $280,234.
- Liquidity Improvement: The company paid off $1.5 million in short-term borrowings. Working capital improved significantly to $1.8 million, and the current ratio increased to 1.30 from 1.05.
- Inventory Management: Inventory levels decreased by $944,439 (14.8%) compared to the prior quarter end.
Outlook, Risks, and Contingencies
- Guidance: Management expects to spend approximately $1 million on research activities in 1997. They anticipate that costs related to software conversion and facility moves will not adversely impact future earnings, and that senior management costs will diminish as a percentage of sales as revenue grows.
- Capital Resources: The company has a $3.5 million line of credit (increased from $2.5 million in Feb 1997), which expires in May 1997. Negotiations to extend the line are underway. Management believes current cash and credit facilities are sufficient for the remainder of the year.
- Legal Proceedings: International Nutrition Company (INC) sued USANA for patent infringement regarding the Proflavanol product. The lawsuit is currently stayed pending a Patent and Trademark Office (PTO) reexamination and a French court ruling. A French court recently ruled INC does not own the patent in question, which could bar INC from proceeding.
- Key Risks:
- Supply Chain: Shortages of Vitamin E Succinate Powder are expected to continue in 1997, requiring product substitutions.
- Regulatory: Risks associated with network marketing laws (FTC, anti-pyramid laws) and FDA regulations on dietary supplements (DSHEA).
- Concentration: Gull Holdings, Ltd. (controlled by Dr. Myron Wentz) owns approximately 63% of the company's stock.
Investor Verification Checklist
- Verify the status of the patent infringement lawsuit with International Nutrition Company and the final outcome of the PTO reexamination.
- Confirm the renewal terms and interest rates of the $3.5 million line of credit expiring in May 1997.
- Monitor the impact of the Vitamin E Succinate Powder shortage on product availability and sales mix.
- Assess the long-term effect of the new customer service software and facility move on operating efficiency and SG&A ratios.
- Review the company's ability to maintain distributor retention rates amidst competitive market pressures.